




## STUDENT VOICES TAKE CENTER STAGE: HIGHLIGHTS FROM MID-TERM GROUP PRESENTATIONS

Students in the GMDP Academy's flagship certification program recently completed their mid-term group presentations—a key milestone that combines scientific depth with cross-functional collaboration. From AI in patient safety to the ethics of clinical trials in pregnant women, each group tackled timely and complex topics with insight and professionalism.

 Read more [here](#) about the presentations and learn more about our certification offerings: [Individual Modules – GMDP Academy](#).

## TABLE OF CONTENTS

Montana's Bold Bet on Experimental Medicine: Implications for Global Medicines Development Professionals • P. 2

---

Gene Editing in Real Time: A Milestone in Personalized CRISPR Therapy • P. 2

---

Breaking New Ground in Pain Relief: What SBI-810 Could Mean for Safer, Smarter Medicines Development • P. 3

---

Non-Communicable Diseases and the Media • P. 3

---

Publication Ethics in an Era of Open Science Upcoming Webinar • P. 4

# MONTANA'S BOLD BET ON EXPERIMENTAL MEDICINE: IMPLICATIONS FOR GLOBAL MEDICINES DEVELOPMENT PROFESSIONALS

Montana has legalized the sale of experimental drugs post-Phase I trials—sidestepping FDA approval and igniting a global debate on access, ethics, and safety.

For GMDP professionals, this raises real-time questions explored in our [Certification in Medicines Development](#) (CMD)—especially around regulatory science and patient autonomy.

📖 Read more [here](#) about the implications for global medicines development, ethical innovation, and professional readiness [1,2,3]



# GENE EDITING IN REAL TIME: A MILESTONE IN PERSONALIZED CRISPR THERAPY



KJ Muldoon is the first patient treated with a fully personalized mRNA-based CRISPR therapy, developed in under six months by leading research centers. This breakthrough targets a rare genetic disorder using advanced gene editing and delivery technology.

The case raises important questions about safety, efficacy, clinical frameworks for “n=1” treatments, and ethics in medicines development. Early results show promising improvements—ushering in a new era of personalized medicine. [3, 4, 5, 6]


👉 [Read more here.](#)

## BREAKING NEW GROUND IN PAIN RELIEF: WHAT SBI- 810 COULD MEAN FOR SAFER, SMARTER MEDICINES DEVELOPMENT

Duke University researchers have developed SBI-810, a novel non-opioid compound that targets pain at its source without the risks of addiction or common side effects like constipation and cognitive impairment. This breakthrough highlights how precision drug design—activating specific pain pathways while avoiding others—can transform treatment for acute and chronic pain.

For GMDP Academy learners, SBI-810 offers a real-world example of how innovative therapies challenge traditional clinical and regulatory approaches, emphasizing ethical and patient-focused drug development. [3, 7]

[👉 Read more here.](#)



## NON-COMMUNICABLE DISEASES AND THE MEDIA: WHY COMMUNICATION MATTERS



At a recent REACH roundtable in Mumbai, healthcare and media experts tackled India's urgent NCD crisis, which causes over 60% of deaths nationwide. They highlighted how media messaging shapes public understanding, prevention, and treatment—especially for women and adolescents.

GMDP Academy emphasizes the vital role of ethical, accurate communication alongside clinical expertise. Our curriculum trains professionals to engage responsibly with media and stakeholders, promoting evidence-based health narratives. [8,9]

[👉 Read more here.](#)

Publication Ethics in an Era of  
**Open Science**  
with Chieko Kurihara

**Offering 1:**  
June 3, 2025  
8:00am EST

→  
**Offering 2:**  
June 4, 2025  
8:00am EST



**Chieko Kurihara**

Special Appointment Professor, Kanagawa Dental University; Senior Researcher/Vice-Chair of the Certified Review Board, National Institutes for Quantum and Radiological Science and Technology, Japan

In an age of open access and rapid data sharing, ethical publishing has never been more important. This public webinar—from the CMD program and facilitated by esteemed expert Chieko Kurihara—offers a foundational look at how to publish responsibly in today’s complex research environment.

### Learning Objectives

- Core principles of ethical publication practices
- Key differences between traditional, open access, peer-reviewed, and predatory journals
- Essentials of the Declaration of Helsinki and Declaration of Taipei
- Real-world cases of falsified publications, including during the COVID-19 pandemic

**OFFERING 1**  
**REGISTRATION**

**OFFERING 2**  
**REGISTRATION**

# REFERENCES

1. Hamzelou, J. (2025, May 14). The first US hub for experimental medical treatments is coming. MIT Technology Review. <https://www.technologyreview.com/2025/05/14/1116428/first-us-hub-for-experimental-medical-treatments/>
2. Silva, H., Stonier, P., Chopra, P., Coots, J., Criscuolo, D., Guptha, S., ... & Vandenbroucke, P. (2024). Blended e-learning and certification for medicines development professionals: Results of a 7-year collaboration between King's College, London and the GMDP Academy, New York. *Frontiers in Pharmacology*, 15, 1417036. [https://doi.org/10.3389/fphar.2024.1417036:contentReference\[oaicite:2\]{index=2}](https://doi.org/10.3389/fphar.2024.1417036:contentReference[oaicite:2]{index=2})
3. Silva, H., Kerpel-Fronius, S., Stonier, P. D., & Dubois, D. J. (Eds.). (2021). Grand challenges in pharmaceutical medicine: Competencies and ethics in medicines development. *Frontiers Media SA*. [https://doi.org/10.3389/978-2-88966-986-8:contentReference\[oaicite:3\]{index=3}](https://doi.org/10.3389/978-2-88966-986-8:contentReference[oaicite:3]{index=3})
4. Penn Medicine. (2025, May). World's first patient treated with personalized CRISPR therapy. <https://www.pennmedicine.org/news/news-releases/2025/may/worlds-first-patient-treated-with-personalized-crispr-therapy>
5. Penn Today. (2025, May). Penn Medicine delivers first in vivo personalized CRISPR therapy. <https://penntoday.upenn.edu/news/penn-medicine-worlds-first-patient-treated-personalized-crispr-gene-editing-therapy-childrens-hospital>
6. The Washington Post. (2025, May 15). CRISPR gene editing breakthrough offers new hope for rare diseases. <https://www.washingtonpost.com/science/2025/05/15/crispr-gene-editing-breakthrough>
7. Inside Precision Medicine. (2025, May 20). Non-Opioid Compound Shows Acute and Chronic Pain Relief Potential. <https://www.insideprecisionmedicine.com/topics/translational-research/non-opioid-compound-shows-acute-and-chronic-pain-relief-potential/>
8. REACH. (n.d.). About Us. Resource Group for Education and Advocacy for Community Health. Retrieved from <https://www.reachindia.org.in>
9. REACH. (2025, April 12). Non-Communicable Diseases emphasize the importance of active media engagement in Public Awareness – Experts. *APN News*. [https://www.apnnews.com/non-communicable-diseases-emphasize-the-importance-of-active-media-engagement-in-public-awareness-experts/Silva, H., Stonier, P., Kerpel-Fronius, S., & Dubois, D. \(2021\). Grand Challenges in Pharmaceutical Medicine: Competencies and Ethics in Medicines Development. \*Frontiers in Pharmacology\*, 12, 666406. <https://doi.org/10.3389/fphar.2021.666406>](https://www.apnnews.com/non-communicable-diseases-emphasize-the-importance-of-active-media-engagement-in-public-awareness-experts/Silva, H., Stonier, P., Kerpel-Fronius, S., & Dubois, D. (2021). Grand Challenges in Pharmaceutical Medicine: Competencies and Ethics in Medicines Development. Frontiers in Pharmacology, 12, 666406. https://doi.org/10.3389/fphar.2021.666406)

---

## Thanks for reading!

The GMDP Academy Newsletter is published twice monthly and is compiled by the following:

**Media Manager:** Whitney English

**Editorial Board:** Pravin Chopra, Jacob Coots

**Operations Office:** Amanda Schmitt, Gustavo Silva, Kit Vale

## CONTACT US:



420 Lexington Ave. Ste. 300  
New York, NY 10170

(332) 333-2438